NO331653B1 - Oralt tolagspreparat med langvarig frigivelse - Google Patents
Oralt tolagspreparat med langvarig frigivelse Download PDFInfo
- Publication number
- NO331653B1 NO331653B1 NO20006503A NO20006503A NO331653B1 NO 331653 B1 NO331653 B1 NO 331653B1 NO 20006503 A NO20006503 A NO 20006503A NO 20006503 A NO20006503 A NO 20006503A NO 331653 B1 NO331653 B1 NO 331653B1
- Authority
- NO
- Norway
- Prior art keywords
- layer
- desloratadine
- pharmaceutically acceptable
- weight
- preparation according
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 230000005923 long-lasting effect Effects 0.000 title 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims abstract description 77
- 229960001271 desloratadine Drugs 0.000 claims abstract description 77
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 37
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 14
- 239000007787 solid Substances 0.000 claims abstract description 9
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000000133 nasal decongestant Substances 0.000 claims abstract description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 32
- 230000003078 antioxidant effect Effects 0.000 claims description 24
- 229960003908 pseudoephedrine Drugs 0.000 claims description 22
- CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 claims description 21
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 21
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 21
- 229960004159 pseudoephedrine sulfate Drugs 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
- 229910052749 magnesium Inorganic materials 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 14
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 15
- 230000000172 allergic effect Effects 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 208000010668 atopic eczema Diseases 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 230000004968 inflammatory condition Effects 0.000 description 11
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 9
- 201000010105 allergic rhinitis Diseases 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- 239000000314 lubricant Substances 0.000 description 9
- 229940091250 magnesium supplement Drugs 0.000 description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- 239000008108 microcrystalline cellulose Substances 0.000 description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 9
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 229940069328 povidone Drugs 0.000 description 8
- 210000002345 respiratory system Anatomy 0.000 description 8
- 235000015165 citric acid Nutrition 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 206010028735 Nasal congestion Diseases 0.000 description 6
- 208000036284 Rhinitis seasonal Diseases 0.000 description 6
- 239000000739 antihistaminic agent Substances 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- QGLIUOLEDZMNSF-UHFFFAOYSA-N 4-(8-chloro-5,6-dihydrobenzo[1,2]cyclohepta[2,4-b]pyridin-11-ylidene)piperidine-1-carbaldehyde Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCN(C=O)CC1 QGLIUOLEDZMNSF-UHFFFAOYSA-N 0.000 description 5
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 5
- 230000001387 anti-histamine Effects 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 5
- 229960003088 loratadine Drugs 0.000 description 5
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 5
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010039085 Rhinitis allergic Diseases 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- -1 lactose Chemical compound 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000011436 cob Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 239000000938 histamine H1 antagonist Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010053779 Allergic cough Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 102000008212 P-Selectin Human genes 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940095564 anhydrous calcium sulfate Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 230000037424 autonomic function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- JHECKPXUCKQCSH-UHFFFAOYSA-J calcium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydrate Chemical compound O.[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JHECKPXUCKQCSH-UHFFFAOYSA-J 0.000 description 1
- ZHZFKLKREFECML-UHFFFAOYSA-L calcium;sulfate;hydrate Chemical class O.[Ca+2].[O-]S([O-])(=O)=O ZHZFKLKREFECML-UHFFFAOYSA-L 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229940031702 hydroxypropyl methylcellulose 2208 Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000012594 liquid chromatography nuclear magnetic resonance Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940073640 magnesium sulfate anhydrous Drugs 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- LFCFXZHKDRJMNS-UHFFFAOYSA-L magnesium;sulfate;hydrate Chemical class O.[Mg+2].[O-]S([O-])(=O)=O LFCFXZHKDRJMNS-UHFFFAOYSA-L 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008219 nasal excipient Substances 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 1
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17275299P | 1999-12-20 | 1999-12-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20006503D0 NO20006503D0 (no) | 2000-12-20 |
| NO20006503L NO20006503L (no) | 2001-06-21 |
| NO331653B1 true NO331653B1 (no) | 2012-02-13 |
Family
ID=22629073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006503A NO331653B1 (no) | 1999-12-20 | 2000-12-20 | Oralt tolagspreparat med langvarig frigivelse |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US6709676B2 (de) |
| EP (3) | EP1674084B1 (de) |
| JP (2) | JP5158919B2 (de) |
| KR (2) | KR20010062543A (de) |
| CN (3) | CN100415223C (de) |
| AR (1) | AR027034A1 (de) |
| AT (2) | ATE329584T1 (de) |
| AU (2) | AU2276801A (de) |
| BR (1) | BR0005938A (de) |
| CA (1) | CA2329172C (de) |
| CO (1) | CO5251421A1 (de) |
| CY (3) | CY1105231T1 (de) |
| CZ (1) | CZ302471B6 (de) |
| DE (3) | DE60042904D1 (de) |
| DK (2) | DK1674084T3 (de) |
| EC (1) | ECSP003835A (de) |
| ES (2) | ES2261158T3 (de) |
| FR (1) | FR08C0004I2 (de) |
| HK (2) | HK1034452A1 (de) |
| HU (1) | HU227538B1 (de) |
| IL (1) | IL140451A (de) |
| LU (1) | LU91403I2 (de) |
| MX (1) | MXPA00012957A (de) |
| MY (1) | MY128658A (de) |
| NL (1) | NL300328I2 (de) |
| NO (1) | NO331653B1 (de) |
| NZ (1) | NZ509034A (de) |
| PE (1) | PE20010952A1 (de) |
| PL (1) | PL209401B1 (de) |
| PT (2) | PT1674084E (de) |
| RU (1) | RU2284182C9 (de) |
| SA (2) | SA06270068B1 (de) |
| SG (2) | SG183573A1 (de) |
| SI (2) | SI1674084T1 (de) |
| SK (1) | SK287105B6 (de) |
| TR (1) | TR200003788A2 (de) |
| TW (1) | TWI222885B (de) |
| WO (1) | WO2001045676A2 (de) |
| ZA (1) | ZA200007714B (de) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287105B6 (sk) * | 1999-12-20 | 2009-12-07 | Schering Corporation | Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním |
| AU2277101A (en) * | 1999-12-20 | 2001-07-03 | Schering Corporation | Stable extended release oral dosage composition |
| US7405223B2 (en) | 2000-02-03 | 2008-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
| JP4318899B2 (ja) * | 2001-08-27 | 2009-08-26 | 第一三共ヘルスケア株式会社 | 抗感冒剤 |
| JP2009132734A (ja) * | 2001-08-27 | 2009-06-18 | Daiichi Sankyo Healthcare Co Ltd | 抗感冒剤 |
| JP4320217B2 (ja) * | 2002-07-10 | 2009-08-26 | 剤盛堂薬品株式会社 | 鼻炎用経口製剤 |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| US7863287B2 (en) * | 2002-12-18 | 2011-01-04 | Wyeth Llc | Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
| US20040253311A1 (en) * | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
| DE602004004453T2 (de) * | 2003-03-12 | 2007-11-08 | Teva Pharmaceutical Industries Ltd. | Stabile pharmazeutische zusammensetzungen mit desloratadin |
| WO2005046650A1 (en) * | 2003-11-12 | 2005-05-26 | Glenmark Pharmaceuticals Limited | Pharmaceutical formulation containing muscle relaxant and cox-ii inhibitor |
| WO2005065047A2 (en) * | 2003-12-23 | 2005-07-21 | Sun Pharmaceutical Industries Limited | Stable oral composition containing desloratadine |
| EP1859791B1 (de) * | 2005-03-10 | 2011-12-07 | Taisho Pharmaceutical Co., Ltd | Dragee |
| US20110081415A1 (en) * | 2005-03-10 | 2011-04-07 | Taisho Pharmaceutical Co., Ltd | Coating apparatus |
| US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
| US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
| EP1728513A3 (de) * | 2005-05-20 | 2007-10-31 | Dr. Reddy's Laboratories, Inc. | Stabile Zusammensetzungen von Desloratadine |
| US20070004671A1 (en) * | 2005-05-20 | 2007-01-04 | Agarwal Sudeep K | Stable desloratadine compositions |
| US20070014855A1 (en) * | 2005-07-12 | 2007-01-18 | Rahul Gawande S | Stable desloratadine compositions |
| JP5269595B2 (ja) | 2005-09-09 | 2013-08-21 | アンジェリーニ ラボファーム リミテッド ライアビリティ カンパニー | １日１回投与用トラゾドン組成物 |
| US20080103746A1 (en) * | 2005-11-30 | 2008-05-01 | Searete Llc, A Limited Liability Corporation | Systems and methods for pathogen detection and response |
| US20080033763A1 (en) * | 2005-11-30 | 2008-02-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems related to receiving nutraceutical associated information |
| US20070124219A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized nutraceutical selection and packaging |
| US20110145009A1 (en) * | 2005-11-30 | 2011-06-16 | Jung Edward K Y | Methods and systems related to transmission of nutraceutical associatd information |
| US8340944B2 (en) * | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| US20080052114A1 (en) * | 2005-11-30 | 2008-02-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods related to nutraceuticals |
| US8297028B2 (en) | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
| US20070289258A1 (en) * | 2006-06-14 | 2007-12-20 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Individualized pharmaceutical selection and packaging |
| US8000981B2 (en) | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
| US20080004905A1 (en) * | 2006-06-28 | 2008-01-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for analysis of nutraceutical associated components |
| US7927787B2 (en) * | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
| US20070136092A1 (en) * | 2005-11-30 | 2007-06-14 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging |
| US10296720B2 (en) * | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US7827042B2 (en) * | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
| US7974856B2 (en) | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
| US20070174128A1 (en) * | 2005-11-30 | 2007-07-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging |
| US20080114577A1 (en) * | 2005-11-30 | 2008-05-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems associated with nutraceutical related assays |
| US20070124176A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
| WO2007096733A2 (en) * | 2006-02-22 | 2007-08-30 | Orchid Chemicals & Pharmaceuticals Limited | Desloratadine-containing formulation stabilized with cyclodextrin |
| CA2541045A1 (en) * | 2006-03-24 | 2007-09-24 | Pharmascience Inc. | A descarbonylethoxyloratadine containing pharmaceutical composition |
| KR101464771B1 (ko) * | 2006-06-01 | 2014-11-26 | 머크 샤프 앤드 돔 코포레이션 | 페닐에프린의 지속 방출용 약제학적 조성물 |
| WO2007143158A2 (en) | 2006-06-01 | 2007-12-13 | Schering-Plough Healthcare Products, Inc. | Sustained release pharmaceutical formulation comprising phenylephrine |
| NZ573174A (en) * | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| RU2008151945A (ru) * | 2006-06-01 | 2010-07-20 | Шеринг Корпорейшн (US) | Лекарственные формы с пульсирующим высвобождением и фармацевтические композиции фенилэфрина |
| US7718649B1 (en) * | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
| CN101848706A (zh) * | 2007-06-01 | 2010-09-29 | 先灵-普劳健康护理产品公司 | 包含底物和含活性成分和聚乙烯醇的包衣的药用组合物 |
| TWI400042B (zh) * | 2007-06-08 | 2013-07-01 | Tci Co Ltd | 食品錠劑 |
| ES2541809T3 (es) | 2007-10-16 | 2015-07-24 | Paladin Labs Inc. | Composición bicapa para la liberación sostenida de acetaminofeno y tramadol |
| PE20091084A1 (es) * | 2007-12-07 | 2009-07-23 | Schering Plough Healthcare | Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal |
| EP2219612A4 (de) | 2007-12-17 | 2013-10-30 | Paladin Labs Inc | Formulierung mit gesteuerter freisetzung und missbrauchsschutz |
| EP2367541B1 (de) | 2008-12-16 | 2014-07-16 | Paladin Labs Inc. | Formulierung mit gesteuerter freisetzung und missbrauchsschutz |
| WO2012151562A1 (en) | 2011-05-04 | 2012-11-08 | Intellikine, Llc | Combination pharmaceutical compositions and uses thereof |
| BR102012030828A2 (pt) | 2012-12-03 | 2014-09-16 | Ems Sa | Composição farmacêutica compreendendo desloratadina e prednisolona e seu uso |
| US10576041B2 (en) | 2016-09-26 | 2020-03-03 | The Procter & Gamble Company | Extended relief dosage form |
| US20180187263A1 (en) | 2017-01-05 | 2018-07-05 | Iowa State University Research Foundation, Inc. | Kits for diagnostic detection and prevention of feedlot bovine respiratory disease |
| CN109966254B (zh) * | 2017-12-28 | 2021-06-01 | 广州医药研究总院有限公司 | 复方地氯伪麻缓释小丸及其制备方法 |
| CN108578406A (zh) * | 2018-04-18 | 2018-09-28 | 曹建华 | 一种用于过敏性鼻炎治疗的组合物 |
| WO2021168133A1 (en) * | 2020-02-19 | 2021-08-26 | Nevakar Inc. | Isoproterenol compositions and methods |
| CN113230235B (zh) * | 2021-04-15 | 2022-11-11 | 海南普利制药股份有限公司 | 含地氯雷他定的复方缓释胶囊及其制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US3940485A (en) | 1973-12-12 | 1976-02-24 | Levinson Harold N | Treatment and pre-treatment of dysmetric dyslexia by improving sequential scanning and ocular fixation abilities and therapeutic compounds |
| US4008796A (en) | 1974-03-26 | 1977-02-22 | General Concrete Of Canada Limited | Control method for feeding items on a conveyor |
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US4282233B1 (en) | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
| AU570306B2 (en) | 1984-02-15 | 1988-03-10 | Schering Corporation | 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo (5,6) cyclohepta (1,2-b) pyridine and its salts. |
| US4552899A (en) | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
| US4783465A (en) | 1984-04-09 | 1988-11-08 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| SE8404467D0 (sv) | 1984-09-06 | 1984-09-06 | Ferrosan Ab | Controlled-release medical preparations |
| US4731447A (en) | 1985-05-13 | 1988-03-15 | Schering Corporation | Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof |
| US4804666A (en) | 1985-08-14 | 1989-02-14 | Schering Corporation | Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines |
| JPS6396126A (ja) | 1986-10-13 | 1988-04-27 | Taisho Pharmaceut Co Ltd | 安定化組成物 |
| US5089496A (en) | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| US4777170A (en) | 1987-02-03 | 1988-10-11 | Heinrich William A | Method to prevent and treat the signs and symptoms of motion sickness |
| GB8707421D0 (en) | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
| US4863931A (en) | 1988-09-15 | 1989-09-05 | Schering Corporation | Antihistaminic fluoro substituted benzocycloheptapyridines |
| US5019591A (en) | 1989-02-17 | 1991-05-28 | Pennsylvania Research Corporation | Method for treating retinopathy and other small vessel disorders associated with diabetes |
| US4990535A (en) * | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| IE68935B1 (en) | 1990-06-22 | 1996-07-24 | Schering Corp | Bis-benzo or benzopyrido cyclohepta piperidene piperidylidene and piperazine compounds compositions and methods of use |
| CA2098198A1 (en) | 1990-12-18 | 1992-06-18 | Ann Christie King | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| PT100502A (pt) | 1991-05-20 | 1993-08-31 | Alza Corp | Composicoes farmaceuticas para aumentar a capacidade de permeacao na pele utilizando monolinoleato de glicerol |
| YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| ES2042421B1 (es) * | 1992-05-22 | 1994-08-01 | Uriach & Cia Sa J | Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina. |
| US5314697A (en) * | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| IT1264517B1 (it) * | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati |
| JP2646972B2 (ja) | 1993-11-01 | 1997-08-27 | 日本電気株式会社 | 多ビットメモリ |
| DE4442999A1 (de) | 1994-12-02 | 1996-06-05 | Hexal Pharma Gmbh | Pharmazeutische Zusammensetzung mit einem aktiven Loratidin-Metaboliten |
| US5595997A (en) | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| US7211582B1 (en) * | 1994-12-30 | 2007-05-01 | Sepracor Inc. | Methods for treating urticaria using descarboethoxyloratadine |
| US7214683B1 (en) * | 1994-12-30 | 2007-05-08 | Sepracor Inc. | Compositions of descarboethoxyloratadine |
| PE11399A1 (es) * | 1996-10-31 | 1999-02-09 | Schering Corp | Combinacion de loratadina y un descongestionante para el tratamiento del asma |
| PE71699A1 (es) * | 1997-02-07 | 1999-08-03 | Sepracor Inc | Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra |
| US5900421A (en) | 1997-02-11 | 1999-05-04 | Sepracor Inc. | Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine |
| US5939426A (en) | 1997-02-28 | 1999-08-17 | Sepracor Inc. | Methods for treating urinary incontinence using descarboethoxyloratadine |
| US6506767B1 (en) | 1997-07-02 | 2003-01-14 | Schering Corporation | 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine |
| IL133420A (en) * | 1997-08-26 | 2004-07-25 | Aventis Pharma Inc | Tablet-shaped pharmaceutical preparation containing a combination of piperidinoalkanol and antihistamines and reduces symptomatic congestion |
| WO1999021556A1 (en) | 1997-10-29 | 1999-05-06 | J-Med Pharmaceuticals, Inc. | Antihistamine/decongestant regimens for treating rhinitis |
| US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| IL139407A0 (en) * | 1998-07-10 | 2001-11-25 | Schering Corp | 8-CHLORO-6, 11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO [5,6] CYCLOHEPTA [1, 2-b] PYRIDINE ORAL COMPOSITIONS |
| US6423721B1 (en) * | 1998-09-10 | 2002-07-23 | Schering Corporation | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines |
| US6051585A (en) | 1998-12-07 | 2000-04-18 | Weinstein; Robert E. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| US6521254B2 (en) | 1998-12-07 | 2003-02-18 | J-Med Pharmaceuticals, Inc. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| US6100274A (en) | 1999-07-07 | 2000-08-08 | Schering Corporation | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
| US6114346A (en) * | 1999-10-22 | 2000-09-05 | Schering Corporation | Treating sleep disorders using desloratadine |
| SK287105B6 (sk) * | 1999-12-20 | 2009-12-07 | Schering Corporation | Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním |
| AU2277101A (en) | 1999-12-20 | 2001-07-03 | Schering Corporation | Stable extended release oral dosage composition |
| MXPA02007558A (es) * | 2000-02-03 | 2002-12-13 | Schering Corp | Tratamiento de condiciones inflamatorias alergicas. |
| US7405223B2 (en) | 2000-02-03 | 2008-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
| EP1289945B1 (de) * | 2000-05-19 | 2004-08-04 | Alcon Inc. | Anilin-disulfid-derivate zur behandlung allergischer erkrankungen |
| US6599913B1 (en) | 2001-06-29 | 2003-07-29 | Schering Corporation | Treating allergic and inflammatory conditions |
| US6679463B1 (en) * | 2003-06-11 | 2004-01-20 | Kye Systems Corp. | Support with multi-stage clamping mechanism |
| WO2005065047A2 (en) * | 2003-12-23 | 2005-07-21 | Sun Pharmaceutical Industries Limited | Stable oral composition containing desloratadine |
| NZ552998A (en) * | 2004-07-16 | 2010-11-26 | Cipla Ltd | Anti-histaminic composition |
-
2000
- 2000-12-19 SK SK1966-2000A patent/SK287105B6/sk not_active IP Right Cessation
- 2000-12-19 WO PCT/US2000/034404 patent/WO2001045676A2/en active Application Filing
- 2000-12-19 AU AU22768/01A patent/AU2276801A/en not_active Abandoned
- 2000-12-20 EC EC2000003835A patent/ECSP003835A/es unknown
- 2000-12-20 NZ NZ509034A patent/NZ509034A/xx not_active IP Right Cessation
- 2000-12-20 MY MYPI20006005A patent/MY128658A/en unknown
- 2000-12-20 SI SI200031046T patent/SI1674084T1/sl unknown
- 2000-12-20 NO NO20006503A patent/NO331653B1/no not_active IP Right Cessation
- 2000-12-20 SG SG2009000175A patent/SG183573A1/en unknown
- 2000-12-20 RU RU2000131897/15A patent/RU2284182C9/ru active
- 2000-12-20 AT AT00311443T patent/ATE329584T1/de active
- 2000-12-20 PL PL344714A patent/PL209401B1/pl unknown
- 2000-12-20 PT PT06006635T patent/PT1674084E/pt unknown
- 2000-12-20 MX MXPA00012957A patent/MXPA00012957A/es active IP Right Grant
- 2000-12-20 DK DK06006635T patent/DK1674084T3/da active
- 2000-12-20 TW TW089127370A patent/TWI222885B/zh not_active IP Right Cessation
- 2000-12-20 DE DE60042904T patent/DE60042904D1/de not_active Expired - Lifetime
- 2000-12-20 HU HU0004989A patent/HU227538B1/hu active Protection Beyond IP Right Term
- 2000-12-20 PT PT00311443T patent/PT1110543E/pt unknown
- 2000-12-20 KR KR1020000079047A patent/KR20010062543A/ko active Search and Examination
- 2000-12-20 ES ES00311443T patent/ES2261158T3/es not_active Expired - Lifetime
- 2000-12-20 EP EP06006635A patent/EP1674084B1/de not_active Expired - Lifetime
- 2000-12-20 CZ CZ20004813A patent/CZ302471B6/cs not_active IP Right Cessation
- 2000-12-20 AR ARP000106791A patent/AR027034A1/es not_active Application Discontinuation
- 2000-12-20 EP EP00311443A patent/EP1110543B1/de not_active Expired - Lifetime
- 2000-12-20 AT AT06006635T patent/ATE441404T1/de active
- 2000-12-20 ES ES06006635T patent/ES2330873T3/es not_active Expired - Lifetime
- 2000-12-20 PE PE2000001375A patent/PE20010952A1/es not_active IP Right Cessation
- 2000-12-20 SG SG200007569-7A patent/SG149667A1/en unknown
- 2000-12-20 DK DK00311443T patent/DK1110543T3/da active
- 2000-12-20 IL IL140451A patent/IL140451A/en active IP Right Grant
- 2000-12-20 CA CA002329172A patent/CA2329172C/en not_active Expired - Fee Related
- 2000-12-20 AU AU72442/00A patent/AU777419B2/en not_active Expired
- 2000-12-20 BR BR0005938-2A patent/BR0005938A/pt not_active Application Discontinuation
- 2000-12-20 CN CNB001373560A patent/CN100415223C/zh not_active Expired - Lifetime
- 2000-12-20 TR TR2000/03788A patent/TR200003788A2/xx unknown
- 2000-12-20 DE DE122008000001C patent/DE122008000001I1/de active Pending
- 2000-12-20 DE DE60028710T patent/DE60028710T2/de not_active Expired - Lifetime
- 2000-12-20 ZA ZA200007714A patent/ZA200007714B/xx unknown
- 2000-12-20 CO CO00096726A patent/CO5251421A1/es active IP Right Grant
- 2000-12-20 CN CN2007101488421A patent/CN101134038B/zh not_active Expired - Fee Related
- 2000-12-20 JP JP2000387675A patent/JP5158919B2/ja not_active Expired - Lifetime
- 2000-12-20 SI SI200030871T patent/SI1110543T1/sl unknown
- 2000-12-20 EP EP09154557A patent/EP2100600A1/de not_active Withdrawn
- 2000-12-20 CN CNA2008101283750A patent/CN101322708A/zh active Pending
-
2001
- 2001-02-25 SA SA06270068A patent/SA06270068B1/ar unknown
- 2001-02-25 SA SA01210740A patent/SA01210740B1/ar unknown
- 2001-06-19 HK HK01105065A patent/HK1034452A1/xx unknown
-
2002
- 2002-06-19 US US10/175,480 patent/US6709676B2/en not_active Expired - Lifetime
-
2003
- 2003-11-03 US US10/699,987 patent/US7618649B2/en not_active Expired - Fee Related
-
2006
- 2006-07-31 CY CY20061101078T patent/CY1105231T1/el unknown
- 2006-10-19 HK HK06111540.6A patent/HK1090840A1/xx not_active IP Right Cessation
-
2007
- 2007-12-14 JP JP2007324053A patent/JP2008081509A/ja active Pending
- 2007-12-21 LU LU91403C patent/LU91403I2/fr unknown
- 2007-12-21 NL NL300328C patent/NL300328I2/nl unknown
- 2007-12-27 CY CY200700031C patent/CY2007031I2/el unknown
-
2008
- 2008-01-22 FR FR08C0004C patent/FR08C0004I2/fr active Active
- 2008-03-17 KR KR1020080024355A patent/KR20080044214A/ko not_active Application Discontinuation
-
2009
- 2009-10-02 US US12/573,022 patent/US8187630B2/en not_active Expired - Fee Related
- 2009-11-16 CY CY20091101200T patent/CY1109636T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO331653B1 (no) | Oralt tolagspreparat med langvarig frigivelse | |
| RU2303440C2 (ru) | Стабильная пероральная дозированная композиция пролонгированного действия | |
| US9492541B2 (en) | Phenylepherine containing dosage form | |
| US20060029664A1 (en) | Dosage form containing carbetapentane and another drug | |
| US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
| KR20090104785A (ko) | 안정한 서방출형의 경구 투여용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP AND DOHME CORP Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US |
|
| MK1K | Patent expired |